• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.86
  • VXN 17.11
  • VXO 11.41
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
()
Last Trade High EPS
Trade Time Low EPS next year
Change 52 week high P/E next year
Bid 52 week low Price/Sale
Ask Volume PEG Growth
Avg Volume Market Cap Open
Book Value Short Ratio Prv Close
Price / Book Stock Exchange Ex-Dividend Date
Dividend Pay Date Dividend/Share Dividend Yield
Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.